{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-124881","form_type":"8-K","ticker":"CHRS","cik":"0001512762","company_name":"Coherus Oncology, Inc.","filed_at":"2024-12-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.644550+00:00","generated_at":"2026-05-29T09:50:09.148880+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Coherus to divest UDENYCA franchise to Intas for up to $558.4M; plans to repay convertible notes","bullets":["Upfront cash $483.4M (subject to inventory adj.) plus up to $75M in net sales milestones ($37.5M each at $300M and $350M thresholds).","Proceeds to fully repay $230M 1.5% convertible notes due April 2026 and buy out $49.1M royalty obligation on UDENYCA.","Post-close cash runway over 2 years; focus shifts to immuno-oncology pipeline (LOQTORZI, casdozokitug, CHS-114).","Transaction requires shareholder approval, HSR, CFIUS; expected close Q1 2025; board unanimously recommends.","Coherus to provide Q4 2024 sales and Q1 2025 cash guidance in early January 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-124881","json":"https://secwatch.observer/filing/0001104659-24-124881.json","markdown":"https://secwatch.observer/filing/0001104659-24-124881.md","text":"https://secwatch.observer/filing/0001104659-24-124881.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1512762/000110465924124881/0001104659-24-124881-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1512762/000110465924124881/tm2429853d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T09:50:09.148880+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}